A novel AKT3 mutation in melanoma tumours and cell lines
about
Main roads to melanomaThe mTOR signalling pathway in human cancerTherapeutic Implications of Targeting AKT Signaling in MelanomaThe PI3K pathway as drug target in human cancerUbiquitin-dependent regulation of phospho-AKT dynamics by the ubiquitin E3 ligase, NEDD4-1, in the insulin-like growth factor-1 responseTargeting RTK Signaling Pathways in CancerThe PI3K/AKT Pathway and Renal Cell CarcinomaDiverse mechanisms of AKT pathway activation in human malignancyPathways and therapeutic targets in melanomaMelanoma: from mutations to medicineActivity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.Melanoma Brain Metastasis: Mechanisms, Models, and MedicineDiscovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitorTargeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatasesTargeting the phosphoinositide 3-kinase pathway in cancerDe novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.Mining mammalian transcript data for functional long non-coding RNAs.Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation.The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.Understanding the biology of melanoma and therapeutic implicationsAkt1 deletion prevents lung tumorigenesis by mutant K-ras.Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic interventionCooperative interactions of PTEN deficiency and RAS activation in melanoma metastasisMolecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic targetTargeted therapy for melanoma: a primer.A novel Akt3 mutation associated with enhanced kinase activity and seizure susceptibility in mice.Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.Driver mutations in melanoma: lessons learned from bench-to-bedside studiesGenotyping of cutaneous melanoma.PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expressionRoles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.New horizons in melanoma treatment: targeting molecular pathways.Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers.
P2860
Q21245465-D7851C03-6339-4D28-B660-3713701B04DAQ24627306-1500694A-8741-4C03-93C7-5DC92B3F5622Q24631438-977F6534-30BD-4F28-BB37-854575036561Q24632283-C753415E-DDF5-4C43-9E89-156A3C7CC6A7Q24632317-93F1EE94-D5EE-45FF-9FE4-9403576D22B5Q26781278-81E52C5D-32BC-4898-AD28-7D106060F054Q26800216-C94731F2-F5A4-41A2-B8BD-B4B7A6C32463Q26851604-9A9ACC65-3AA9-4093-8F03-06176B5E3E41Q26865736-44E4D5A4-E258-4F15-96F5-661220D85780Q27024061-317AB6D6-C96D-4AD0-8794-945D3751A36BQ27851482-596A64F9-6B4D-4CF6-8D96-69D36E73F9CBQ28069421-1B0CB76B-06E7-41B4-9B24-0945F058A487Q28540161-6847487C-8500-4EBF-80A2-8039F619D0A9Q28550300-E45B55D0-AC7C-478C-B3A0-72435D9141FDQ29248612-BB8E4344-28B4-481E-8CD7-2C9F100487F1Q29615809-686243B6-5F39-4961-B0CC-AD864FE5689BQ30647055-B079446E-397A-4D86-9374-C6EC3E034064Q33399049-E2B9D7BD-A64F-41A3-BCCC-E628B1661EBEQ33414685-4F55CDE1-C160-423A-A8BF-AE0766AA99AAQ33567626-E141279B-918E-44E0-AA1E-564EA2C295D7Q33664428-F483AB5C-DD29-4376-9043-9477F569103AQ33770769-065AB56C-32A9-4BC2-A8D2-5C63841F5A67Q33884726-7121386A-14DA-4ABA-8D4F-60B2DCC76EFCQ33978378-238B0061-31CA-4352-875A-E6151608BAD9Q34049042-69D58EA1-6597-445C-8D7E-83875CB614BFQ34069302-CA2E73CE-FD68-4C23-97F5-D9996C8D9C94Q34253185-23568FBA-0B43-40C5-BD9C-72E81D67A06AQ34286759-24579E69-3C1E-4678-AA8C-BA4C5C90326BQ34338564-A1375194-E866-43AD-A68F-178D75378B26Q34438536-BCE29E2C-2C3B-4054-8931-5579FDF61A32Q34540273-CFBDA0E4-152B-4F60-8AF6-313E1C5FE586Q34549521-6446584C-1C94-4A7B-91A6-78B43428F998Q34592027-21BA6554-0504-4E2F-ABFA-A7D9CCA145B7Q34639532-C8B61E5A-84E3-4864-A75F-4A413C617931Q34667738-62DCF60C-6F08-49B2-ABD0-87FAF1564BECQ34761941-E966C641-C5F3-496F-88EC-4735C9B3E4FEQ34966603-8FCDC0AE-F3BB-4B23-B87D-E28A696A6F78Q34986188-EB58B380-BC9B-4266-8079-77994046D3FEQ35033377-3FBFDA60-9F57-4C63-B3AE-3C4F35F68777Q35097324-2BB66498-3588-4E3D-B100-49E8A467CD01
P2860
A novel AKT3 mutation in melanoma tumours and cell lines
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A novel AKT3 mutation in melanoma tumours and cell lines
@en
type
label
A novel AKT3 mutation in melanoma tumours and cell lines
@en
prefLabel
A novel AKT3 mutation in melanoma tumours and cell lines
@en
P2093
P2860
P356
P1476
A novel AKT3 mutation in melanoma tumours and cell lines
@en
P2093
J E Gershenwald
K Stemke-Hale
M A Davies
T L Calderone
V G Prieto
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604637
P407
P577
2008-09-23T00:00:00Z